FDA Fast-Tracks Promising Pancreatic Cancer Drug

The FDA has given fast-track status to daraxonrasib, a new drug showing promise in treating pancreatic cancer. This drug is designed to obstruct cancer signals linked to the RAS gene.

Early Clinical Trial Results

Daraxonrasib has completed an initial clinical trial, assessing its safety and effectiveness. The trial involved 168 patients with advanced pancreatic cancer, all of whom had tumors with mutations in the RAS gene and had previously undergone chemotherapy.

“More than 90% of pancreatic cancers carry harmful RAS gene mutations,” researchers explained.

Response and Side Effects

At the 300-milligram dose intended for future phase 3 trials, about 30% of patients experienced positive responses. Overall, 90% of patients saw their cancer either shrink or stop worsening.

Common side effects included rash, mouth inflammation, nausea, and diarrhea. Despite these, most patients tolerated the treatment well.

Potential Shift in Cancer Treatment

Dr. Brian Wolpin, a lead investigator, highlighted that if future trials support these findings, daraxonrasib could become a targeted therapy for nearly all patients with advanced pancreatic cancer.

“If effective in larger trials, it could significantly change pancreatic cancer treatment,” Wolpin stated.

Research Encourages Optimism

Brian Slomovitz from Mount Sinai Medical Center, although not involved in the study, expressed optimism over the drug’s potential. He noted the unprecedented doubling of survival time in pretreated patients could reshape treatment standards.

Slomovitz emphasized the importance of further evaluation to confirm its benefits and safety.

The drug remains investigational and is not yet a cure, underscoring the need for ongoing research to integrate it effectively into treatment plans for maximum benefit.